Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew ...
Incannex reports Q2 EPS (33c) vs (33c) last year
Reports Q2 revenue $12,000. “Patients with obstructive sleep apnea need new and convenient therapeutic options to manage this serious, chronic ...